Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | DRD1 | P21728 | 5/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010135 | 0.84 | SLC6A2 (0.56) | MAOAMAOBHTR2A | |
| SCHEMBL15131035 | 0.84 | SLC6A2 (0.56) | MAOAMAOBHTR2A | |
| SCHEMBL19010138 | 0.84 | SLC6A2 (0.56) | MAOAMAOBHTR2A | |
| SCHEMBL26608671 | 0.81 | SIGMAR1 (0.56) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| SCHEMBL2276424 | 0.79 | PRCP (0.53) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| SCHEMBL9317823 | 0.77 | SIGMAR1 (0.51) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| Hydrochloric Acid SCHEMBL7568493 | 0.77 | SIGMAR1 (0.54) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| SCHEMBL8011446 | 0.77 | PRCP (0.56) | SIGMAR1DRD1MAOAMAOBDRD2 | |
| SCHEMBL30298337 | 0.76 | PRCP (0.52) | SIGMAR1PRCP | |
| SCHEMBL30298334 | 0.76 | PRCP (0.52) | SIGMAR1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | SIGMAR1 4406/4885DRD1 4832/4885MAOA 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.